United Kingdom (UK)
Recombinant monoclonal antibody to DR5. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma TRA-8.
UniProt Accession Number of Target Protein: O14763
Alternative Name(s) of Target: TRAILR2; TNFRSF10B; TRAIL receptor 2; tumor necrosis factor receptor superfamily member 10B
Immunogen: The antibody was raised by immunizing BALB/c mice with a fusion protein containing the extracellular portion of human DR5 and the Fc portion of human IgG1.
Specificity: The antibody is specific to human DR5 and does not bind other TRAIL receptors, other members of the TNF-receptor superfamily, or the murine homolog of DR5.
Application Notes: The antibody has been characterised using Western blot and ELISA. It induces apoptosis in primary hepatocellular carcinoma cells and established liver cancer cell lines, but not normal human hepatocytes (Ichikawa et al., 2001). The antibody has been reported to function in flow cytometry to detect cell-surface expression of DR5 on Cos-7 cells transfected with full-length human DR5. This antibody has been demonstrated to have therapeutic benefits in the treatment of cancer in vivo and ex vivo (Buchsbaum et al., 2003; PMID: 14506165) (Straughn Jr et al., 2006; PMID: 16271751) (Estes et al., 2007; PMID: 17303227).
Antibody first published in:
Ichikawa et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nat Med. 2001 Aug;7(8):954-60. PMID:11479629
Note on publication:
Describes the generation of the antibody, its characterisation and its function in triggering tumor apoptosis.
Immunofluorescence staining of HepG2 cells using anti-DR5 antibody (Ab00983) TRA-8. Immunofluorescence analysis of paraformaldehyde fixed HepG2 cells stained with the chimeric rabbit IgG version of TRA-8 (Ab00983-23.0) at 10 µg/ml followed by Alexa Fluor® 488 secondary antibody (2 µg/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab00983-23.0, DAPI, merged channels and an isotype control. The isotype control was stained with anti-Fluorescein antibody (Ab00102-23.0) followed by Alexa Fluor® 488 secondary antibody.